Non-Cystic Fibrosis Bronchiectasis (NCFB) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic, progressive lung disease that causes the airways to become permanently widened and abnormal. People with NCFB often have chronic coughs, produce mucus, and get repeated lung infections. The symptoms of NCFB can range from mild to severe. Some people have no symptoms, while others may experience massive lung bleeding or respiratory failure. The most common symptom of NCFB is a chronic cough. Many people with NCFB have a cough that produces mucus for over 30 years before they are diagnosed. Other common symptoms include shortness of breath, fatigue, chronic sinus infections, and ear, nose, and throat surgery. A smaller number of people with NCFB experience mild, intermittent bleeding from the lungs. However, in some cases, the bleeding can be severe and life-threatening. Many people with NCFB also require frequent hospital admissions for repeated pneumonia. Depression and anxiety are common in people with NCFB and can significantly affect their quality of life.
Thelansis’s
“Non-Cystic Fibrosis Bronchiectasis (NCFB) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Non-Cystic
Fibrosis Bronchiectasis (NCFB) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Non-Cystic Fibrosis
Bronchiectasis (NCFB) across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Non-Cystic
Fibrosis Bronchiectasis (NCFB) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment